ClinicalTrials.gg
CompletedNCT02452112Updated Nov 14, 2017

Efficacy and Safety of 5% Lidocaine Patch With Placebo Patch in Subjects With Herpes Zoster Associated Pain

A Phase 2/3 interventional study of 5% Lidocaine patch and Placebo in Herpes Zoster Pain, sponsored by Mundipharma (China) Pharmaceutical Co. Ltd. Completed at 21 sites in China. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2017-11-14.

Sponsored by Mundipharma (China) Pharmaceutical Co. Ltd (part of Mundipharma) · Phase 2/3, Interventional, and Treatment

From the registry’s dates

  • Registered 6 months after the study started (first participant enrolled Nov 2014, registered May 2015).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
243
Allocation
Randomized
Ages
18 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 51 studies in Herpes Zoster with a site in China — 26 open to participants now, 31 under way, 3 of them phase 3. Herpes Zoster · China.

Enrollment
26th of 45
243 · median 519
Started
2014
with 1 other
Phase 2/3
Only one
of the 51
Registered
3rd of 51
by date

Among the 51 studies in Herpes Zoster with a site in China, this one is the 26th largest by enrollment of the 45 interventional ones that give a count, is one of 2 that started in 2014, is the only one in phase 2/3, and was the 3rd registered.

Herpes Zoster

299 studies on the registry are indexed under Herpes Zoster; 55 are open to participants now.

Browse Herpes Zoster studies →

Open to participants now

26 of the 51 studies in Herpes Zoster with a site in China are open now. Recruiting first, the newest first:

21 more — sign in →

All 26 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 37 Herpes Zoster studies recruiting now, 26 (70%) set no upper age limit and 6 (16%) stop at 75 or younger; 3 take children under 18; 13 take healthy volunteers.

This study: 18 Years to 85 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 51 studies in Herpes Zoster with a site in China, or all of them as a file.
02

Study summary

This is a randomized, double-blind, placebo-controlled study designed to assess the efficacy and safety of 5% lidocaine patch, following placebo or active patch applications in placebo insensitive subjects.

03

Conditions studied

  • Herpes Zoster Pain
04

Who can participate

Ages eligible
18 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female subjects 18 to 85 years of age.
  2. Subjects must have herpes zoster associated pain present for ≥1 months after healing of the acute herpes zoster skin rash and not located on the face, scalp; the diagnosis will be based on physical examination and review of available medical records confirming an episode of herpes zoster.
  3. Herpes zoster associated pain must be of at least moderate severity, defined as the average pain level ≥40 mm on a 100 mm visual analog scale (VAS slide ruler)

Exclusion criteria

Exclusion Criteria:

  1. Subjects with signs of cord or brainstem injury from herpes zoster.
  2. Presence of another pain problem of greater severity than their herpes zoster associated pain.
  3. Subjects who have undergone neurolytic nerve blocks or ablative neurosurgical procedures for control of herpes zoster associated pain
05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
243 participants (actual)

Study arms

  • Active comparator
    Lidocaine

    Active arm with administration of active 5% Lidocaine patch

    Drug: 5% Lidocaine patch

  • Placebo comparator
    Placebo

    Placebo arm with administration of placebo patch

    Drug: Placebo

Interventions

  • 5% Lidocaine patch to be placed on the site of pain

    Also known as: Lignopad

  • DrugPlacebo

    Placebo patch to be placed on the site of pain

06

What researchers measure

Primary outcomes

  1. Change of VAS score

    Mean change in the mean pain VAS score

    Time frame: over 24 hour from baseline to the post-treatment over time during double-blind period

07

Study locations

21 sites
  • Beijing University People's Hospital
    Beijing, Beijing 100044, China
  • Air force general hospital
    Beijing, China
  • Beijing friendship hospital
    Beijing, China
  • Beijing university first hospital
    Beijing, China
  • Beijing university third hospital
    Beijing, China
  • The first affiliated hospital of Jilin university
    Changchun, China
  • Xiangya hospital central south university
    Changsha, China
  • South West Hospital
    Chengdu, China
  • First affiliated hospital of Chongqing medical university
    Chongqing, China
  • The first affiliated hospital of Dalian university
    Dalian, China
  • Guangzhou general hospital
    Guangzhou, China
  • The first affiliated hospital of Zhejiang university
    Hangzhou, China
  • Shandong dermatology hospital
    Jinan, China
  • The second affiliated hospital of Kunming medical college
    Kunming, China
  • China dermatology research center
    Nanjing, China
  • Shanghai Huashan hospital
    Shanghai, China
  • Shanghai Ruijin Hospital
    Shanghai, China
  • Shengjing Hospital
    Shenyang, China
  • The fourth affiliated hospital of Hebei medical university
    Shijiazhuang, China
  • General hospital of Tianjin medical university
    Tianjin, China
  • Xijing Hospital
    Xian, China
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Nov 2014 to primary completion in Dec 2015, 13 months.

How these figures are worked out, and which studies are left out of them.

Registered
May 20, 2015
First posted
May 22, 2015
StartActual
Nov 2, 2014
Primary completionActual
Dec 30, 2015
CompletionActual
Oct 30, 2016
Last update
Nov 14, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 14, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02452112
Responsible party
Sponsor
First posted
May 22, 2015
Start date
Nov 2, 2014
Primary completion
Dec 30, 2015
Completion
Oct 30, 2016
Last update
Nov 14, 2017

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Lidoderm

Start the discussion